ArticleOphthalmology and therapy2026
Anterior Suprachoroidal Fluid Following Photodynamic Therapy for Chronic CSC: An Anterior-Segment Optical Coherence Tomography Study.
Article in Ophthalmology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe early anterior uveal response after photodynamic therapy (PDT) in chronic central serous chorioretinopathy (CSC) has not been systematically characterized. This study aimed to determine the incidence of anterior supraciliary/suprachoroidal fluid (SCF) detected by anterior-segment optical coherence tomography (AS-OCT) after half-fluence PDT and to examine its association with macular and choroidal structural changes.
methodsIn this retrospective single-center case series, 29 eyes of 29 patients with chronic CSC treated with half-fluence PDT were analyzed. AS-OCT and macular OCT were obtained at baseline and day 3, and 1 month. Eyes were classified as SCF-change (new or increased SCF at day 3) or SCF-stable. The primary outcome was the incidence of SCF at day 3. Secondary outcomes included best-corrected visual acuity (BCVA), central macular thickness (CMT), central choroidal thickness (CCT), and the incidence of PDT-induced acute exudative maculopathy (PAEM). Continuous variables are presented as median [interquartile range], and nonparametric statistical tests were used.
resultsSCF was detected in 4/29 eyes (13.8%) at baseline and in 14/29 eyes (48.3%) at day 3. Eleven eyes (37.9%) were classified as SCF-change and 18 (62.1%) as SCF-stable. In the SCF-change group, CMT increased significantly from 366.0 [237.0, 405.0] μm at baseline to 490.0 [263.0, 691.5] μm at day 3 (p = 0.002). In contrast, the SCF-stable group showed no significant change. The magnitude of CMT increase was significantly greater in the SCF-change group (p = 0.003). PAEM occurred more frequently in the SCF-change group than in the SCF-stable group (7/11 vs. 2/18; Fisher's exact test, p = 0.010; odds ratio 14.0, 95% confidence interval 2.06-95.09).
conclusionsAnterior SCF frequently appeared in the early phase after PDT for chronic CSC and was associated with greater short-term increases in macular thickness and a higher incidence of PAEM. Detection of anterior SCF by AS-OCT may provide a useful early imaging marker reflecting acute choroidal reactivity following PDT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.